The Influence of a KDT501, a Novel Isohumulone, on Adipocyte Function in Humans.

ABSTRACT:

Objective

In a phase II clinical trial in nine obese, insulin-resistant humans, we observed that treatment with KDT501, a novel isohumulone drug, increased total and high-molecular weight (HMW) adiponectin in plasma. The objective was to determine whether KDT501 increased adiponectin secretion from subcutaneous white adipose tissue (SC WAT) and the underlying mechanism(s).

Methods

Nine obese participants with either prediabetes or with normal glucose tolerance plus three features of metabolic syndrome were part of the study. SC WAT biopsies were performed before and after 28 days of KDT501 treatment in a clinical research setting. In addition, a cold stimulus was used to induce thermogenic gene expression. Adiponectin secretion was measured, and gene expression of 130 genes

SUBMITTER: Finlin BS 

PROVIDER: S-EPMC5626816 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature